Cannabis Report
Home > Boards > US Listed > Medical - Drugs >

Precipio Inc. (PRPO)

Add PRPO Price Alert      Hide Sticky   Hide Intro
Moderator: beambe
Search This Board: 
Last Post: 9/18/2018 10:02:03 AM - Followers: 77 - Board type: Free - Posts Today: 0


Link to coporate website:

Share Structure
Market Value1 $40,142,705 a/o May 10, 2013
Shares Outstanding 88,225,725 a/o Mar 13, 2013
Float Not Available
Authorized Shares 100,000,000 a/o Aug 02, 2011
Par Value 0.01

Wells Fargo Bank Minnesota, N.A.
Shareowner Services
P.O. Box 64854
St. Paul, MN 55164-0854
Phone: 877-602-7611

Transgenomic is a global biotechnology company that provides unique products and services for automated high sensitivity genetic variation and mutation analysis. Our offerings include systems, products, discovery and laboratory testing services to the academic and medical research, clinical laboratory and pharmaceutical markets in the fields of pharmacogenomics and personalized medicine.

Transgenomic offers its WAVE® DHPLC Systems and associated consumables. These systems are specifically designed for use in genetic variation detection and single- and double-strand DNA/RNA analysis and purification and have broad applicability to genetic research. To date there have been over 1600 systems shipped to more than 30 countries.

Transgenomic's SURVEYOR® Mutation Detection Kits and the SURVEYOR Check-It Kit provide reagents and protocols for the detection of mutations in DNA.

Transgenomic's Cytogenetics offering includes HANABI automated chromosome harvesting systems that improve laboratory productivity with consistent quality compared to manual methods.

Transgenomic Clinical Reference Laboratory provides reference laboratory services specializing in molecular diagnostics including Mitochondrial Disorders, Oncology and Hematology, Molecular Pathology and Inherited Diseases.

Transgenomic Genomic Research Services is a CRO for pharmacogenomic, translational research and clinical trials.

Colorectal Cancer Testing

Very important AMGEN signs collaberation deal with Mgmt:

"Another potential meaningful near-term contributor to the Lab Services segment (as well as to the Diagnostic Tools segment) relates to the recently consummated agreement with Amgen (NasdaqGS:AMGN) whereby the two companies are collaborating on a KRAS an NRAS gene mutation assay kit to screen patients for colorectal cancer.  The RAScan test is currently available for research use only (RUO) in the U.S. (which will run through Lab Svcs) and for clinical use in Europe - which could help accelerate instrument placements (through Menarini) as well as increase consumables sales"

CRC RAScan™ is a new mutation detection test designed to screen for selected KRAS and NRAS mutations (collectively referred to as “RAS mutations”), in patients with metastatic colorectal cancer (mCRC).The identification of these RAS mutations can give physicians important clinical information to help them make better treatment decisions for their mCRC patients.

KRAS and NRAS are part of the RAS family of genes which encode proteins involved in transmitting signals within cells. When Ras proteins are “switched on” by incoming signals, other genes involved in cell growth, differentiation, and survival are activated. Mutations in KRAS, NRAS and other related genes can lead to Ras proteins becoming permanently activated, causing overactive signaling even in the absence of incoming signals, and can lead to the uncontrolled cell growth that characterizes cancer. Mutations that permanently activate Ras proteins are found in ~25% of human tumors and up to 90% of certain cancers. About 40% of colorectal tumors carry KRAS gene mutations and these mutations have been associated with poor response to EGFR antagonists such as cetuximab and panitumumab. Therefore KRAS mutation status can be used to determine whether or not a patient with colorectal cancer will respond to anti-EGFR therapy.

The CRC RAScan test can identify mCRC patients who have RAS mutations at levels that cannot be detected using traditional Sanger Sequencing methods.

CRC RAScan™ for Colorectal Cancer Tumor Testing is available immediately from Transgenomic’s CLIA-certified laboratory in the United States. For more information on this test, click here.

CRC RAScan Mutation Detection Kits will soon be available in the U.S for research use only. CRC RAScan Mutation Detection Kits include the following kits based on Transgenomic's proprietary SURVEYOR® Nuclease technology:

  • KRAS Exon 2
  • KRAS Exons 3 & 4
  • NRAS Exons 2, 3 & 4

Zacks analyst ~ OUR 2013 OUTLOOK~

We've again made some updates to our model.  We now model 2013 revenue of $32.4 million, implying growth of 3% from 2012.  We look for Laboratory Services and Instruments to generate revenue of $20.0 million (+4%) and $12.4 million (+2%), respectively.  We think net income and EPS come in at ($12.7) million and ($0.14).


New Analyses Identify Predictive Biomarkers For Vectibix® (Panitumumab) In Patients With Metastatic Colorectal Cancer

Biomarker Analysis From Phase 3 PRIME ('203) Study and Phase 2 PEAK ('509) Study Link Additional RAS Gene Mutations to Vectibix Clinical Response

THOUSAND OAKS, Calif., May 15, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from three analyses of Vectibix® (panitumumab) in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, as a first-line treatment for metastatic colorectal cancer (mCRC). These analyses include the description of new predictive biomarkers of clinical response to Vectibix, activating mutations in KRAS (beyond exon 2) and mutations in NRAS, collectively referred to as RAS.

"Amgen helped establish KRAS gene mutation as a biomarker for lack of response to anti-EGFR treatment," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "The identification of new biomarkers may further help to identify appropriate patients with this incurable disease for such treatment."


Contact Information:
Phone: (402) 452-5437

SEC Filings:

Press Releases:

Cannabis Report
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#1961   Back in with a starter. mgland 09/18/18 10:02:02 AM
#1960   Here's the problem. Addressing the issues doesn't mean SidVicious 08/23/18 07:50:12 PM
#1959   From today's PRPO CC aries4747 08/23/18 12:15:58 PM
#1958   Would you care to elaborate on this statement? laser777 08/23/18 11:51:22 AM
#1957   Good buyers opportunity today. Expect big things next week. Penny pinching 08/23/18 11:18:57 AM
#1956   PRPO files 10Q. aries4747 08/16/18 05:51:27 PM
#1955 beambe 08/09/18 12:12:55 PM
#1954   VolumeOMG beambe 08/08/18 05:25:00 PM
#1953   Revenues are increasing and growing acceptance in the awaitingamove 08/02/18 01:24:05 AM
#1952   Why would this go to $1 laplova 08/01/18 06:57:46 PM
#1951 beambe 08/01/18 04:20:37 PM
#1950   OMG-Volume NEWS ? beambe 08/01/18 04:17:41 PM
#1949   Patience beambe 08/01/18 03:48:55 PM
#1948   PRPO (.47): Late day pps and volume boom. aries4747 08/01/18 03:42:43 PM
#1947   It will go to $1 tomorrow as the SidVicious 07/26/18 11:13:12 PM
#1946   Will it be sell off in the morning RavenEyesStocks 07/26/18 04:17:36 PM
#1945   Thanks. I’m with ya. Hopefully good things are coming. rightothesky 07/25/18 07:40:03 AM
#1944   thats a solid price. I have 110K+ shares PennyStockTrader2 07/25/18 06:09:06 AM
#1943   I got about 20k shares of this @ rightothesky 07/24/18 10:55:38 PM
#1942   Took about 10% off the table on that PennyStockTrader2 07/24/18 07:28:23 PM
#1941   Yeah, that you’ll be wrong SidVicious 07/22/18 11:40:25 PM
#1940   Any thoughts on this week? Anyone have predictions? RavenEyesStocks 07/22/18 09:03:00 PM
#1939   BIG NEWS COMING NEXT WEEK IMO Its_About_To_Blow 07/21/18 02:28:38 PM
#1938   Can’t wait! SidVicious 07/21/18 12:06:48 AM
#1937   $1+ next week IMO Its_About_To_Blow 07/20/18 11:32:06 PM
#1936   I held all 1200 shares. Down a good RavenEyesStocks 07/20/18 09:17:05 PM
#1935   We are going to fly and you will Its_About_To_Blow 07/20/18 08:58:26 PM
#1934   I'm not 100% sure here. The MM Upset Wookie 07/20/18 11:25:35 AM
#1933   So much for momentum. Went up to 60 SidVicious 07/20/18 10:45:34 AM
#1932   incorrect as usual. SidVicious 07/20/18 09:57:12 AM
#1931   Chargeeeeeeeeeee! Hit the ask people. Don’t bid sit rightothesky 07/20/18 09:39:01 AM
#1930   Going to buy more shares at open. This rightothesky 07/20/18 09:10:37 AM
#1927   Might want to try another line of work. SidVicious 07/19/18 08:35:58 PM
#1926   I saw it I believe this will have RavenEyesStocks 07/19/18 06:29:17 PM
#1925   Nice cup and handle forming on the 5 day Its_About_To_Blow 07/19/18 02:59:39 PM
#1924   May turn green by close! Its_About_To_Blow 07/19/18 02:07:00 PM
#1923   You would have to be stupid to sell Its_About_To_Blow 07/19/18 02:05:47 PM
#1922   Exactly!! rightothesky 07/19/18 12:02:10 PM
#1921   We got the DIP, now it’s time for rightothesky 07/19/18 11:33:04 AM
#1920   About to start that run to $1+! Its_About_To_Blow 07/19/18 11:28:08 AM
#1919   Do not give these bastard son of my Its_About_To_Blow 07/19/18 11:21:23 AM
#1918   DO NOT SELL!!! IF YOU DO SET SELLS HIGH Its_About_To_Blow 07/19/18 11:19:52 AM
#1917   Hold the line people!!! Its_About_To_Blow 07/19/18 11:19:20 AM
#1916   Boom back up Its_About_To_Blow 07/19/18 11:16:54 AM
#1915   You are blowing nonsense. Odds are the stock SidVicious 07/19/18 08:55:07 AM
#1914   I'm holding! Thank you RavenEyesStocks 07/19/18 08:18:16 AM
#1913   Only messed up if you sell for a loss! Its_About_To_Blow 07/19/18 07:08:31 AM
#1912   Dont let clay and his goons scare you. Its_About_To_Blow 07/19/18 07:05:38 AM
#1911   Dont get scared out of your shares. She Its_About_To_Blow 07/19/18 07:04:50 AM
#1910   Read: license agreements coming! Its_About_To_Blow 07/19/18 07:03:08 AM